Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks With Remarkable Resilience.
Moderna snapped a four-day losing streak on Wednesday, jumping 7.49 percent to finish at $49.06 apiece, as investors positioned portfolios ahead of its participation in a conference next week.
In a notice to investors, Moderna Inc. (NASDAQ:MRNA) said that it is set to join in the Goldman Sachs’ 47th Annual Global Healthcare Conference on Tuesday, June 9. Investors are expected to watch for the company’s updates on its pipeline progress.
Photo by M. A. Arkhipov on Shutterstock
Apart from Goldman Sachs, the company is also expected to hold its annual shareholders’ meeting called Science Day on June 25, 2026, where it will showcase its latest advancements in the mRNA platform science, basic research, and pipeline developments.
In other news, Moderna Inc. (NASDAQ:MRNA) presented, along with Merck, the five-year data for Intismeran Autogene in combination with Keytruda in patients with high-risk stage 3 and 4 melanoma at the recently concluded 2026 ASCO annual meeting.
According to Moderna Inc. (NASDAQ:MRNA), patients who received Intismeran Autogene in combination with Keytruda successfully reduced cancer recurrence and death risk by 49 percent, as well as its ability to spread to distant parts of the body by 59 percent.
While we acknowledge the potential of MRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
